• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

    2/14/23 12:26:09 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PALI alert in real time by email
    SC 13G/A 1 pali-sc13ga_123122.htm AMENDMENT TO FORM SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Palisade Bio, Inc.

     

    (Name of Issuer)  

     

    Common Stock, par value $0.01 per share

     

    (Title of Class of Securities) 

     

    696389204  

     

    (CUSIP Number)  

      

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Page 2 of 9

      

    CUSIP No.    696389204    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES 

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING 

    0 

     
    6

    SHARED VOTING POWER 

    0 

     
    7

    SOLE DISPOSITIVE POWER 

    0 

     
    8

    SHARED DISPOSITIVE POWER 

    0 

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    0 

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 

    0%

     
    12

    TYPE OF REPORTING PERSON 

    IA, PN 

     
             

     

    Page 3 of 9

     

    CUSIP No. 696389204    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES 

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING 

    0 

     
    6

    SHARED VOTING POWER 

    0 

     
    7

    SOLE DISPOSITIVE POWER 

    0 

     
    8

    SHARED DISPOSITIVE POWER 

    0 

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    0 

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 

    0%

     
    12

    TYPE OF REPORTING PERSON 

    PN 

     
             

     

    Page 4 of 9

     

    CUSIP No. 696389204    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES 

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING 

    0 

     
    6

    SHARED VOTING POWER 

    0 

     
    7

    SOLE DISPOSITIVE POWER 

    0 

     
    8

    SHARED DISPOSITIVE POWER 

    0 

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    0 

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 

    0%

     
    12

    TYPE OF REPORTING PERSON 

    OO 

     
             

     

    Page 5 of 9

    CUSIP No. 696389204    

     

    Item 1(a).   Name of Issuer:                                                         Palisade Bio, INC. (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:   7750 El Camino Real, Suite 5200 

    Carlsbad, California 92009 

         
    Item 2(a).  

    Name of Person Filing:  

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LP, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund. 

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. 

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.  

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.01 per share (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 696389204
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

    Page 6 of 9

     

    CUSIP No. 696389204    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. 

     

    As of the Reporting Date the Firm does not control any shares of the Issuer. 

     

     

    Page 7 of 9

     

    CUSIP No . 696389204    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 14, 2023  
           
      Altium Capital Management, LP  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
         
      By: Altium Growth GP, LLC  
      Its: General Partner  
           
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
       
      Altium Growth GP, LLC  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

    Page 8 of 9

    EXHIBIT INDEX

     

    EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
       
      Members of Group

      

     

     

    Get the next $PALI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PALI

    DatePrice TargetRatingAnalyst
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    More analyst ratings

    $PALI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:58:18 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO, CFO Finley John David

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:56:42 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wei Binxian converted options into 388 units of Comon Stock, increasing direct ownership by 83% to 855 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      11/22/24 4:00:10 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    SEC Filings

    See more

    $PALI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palisade Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - PALISADE BIO, INC. (0001357459) (Filer)

      5/2/25 4:11:24 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Palisade Bio Inc.

      10-K - PALISADE BIO, INC. (0001357459) (Filer)

      3/24/25 4:20:12 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Palisade Bio Inc.

      424B3 - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 5:30:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

      Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from

      5/6/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

      Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA. Details of the oral presentation are as follows: Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient OutcomesTitle: Improving

      5/1/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

      Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025 Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune,

      4/9/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      11/14/24 3:35:13 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/14/24 2:54:03 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/13/24 8:10:04 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/29/24 3:47:14 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/28/24 6:02:01 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/7/24 8:30:10 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

      Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

      2/2/22 7:38:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group initiated coverage on Palisade Bio with a new price target

      Maxim Group initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

      8/31/21 8:02:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Financials

    Live finance-specific insights

    See more
    • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

      Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

      3/16/22 8:00:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Leadership Updates

    Live Leadership Updates

    See more
    • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

      Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

      12/17/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Appoints Margery Fischbein to its Board of Directors

      Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

      5/7/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

      Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

      2/8/24 2:40:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care